Molecular characterization of AML-MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC-defining criteria, TP53 allelic state, or TP53 variant allele frequency.
Cancer medicine（2023）
摘要
Our study suggests that TP53 AML-MRC defines a very-high-risk subentity of AML in which novel therapies should be explored.
更多查看译文
关键词
AML risk stratification,AML-MRC,TP53 mutation,next-generation sequencing
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要